The Lancet: Findings from a Phase I study completed by Altasciences and Novo Nordisk A/S to determine the safety, tolerability, pharmacokinetic, and pharmacodynamics of a drug combination for weight management
Share this page
Sign up for exclusive content
Join our list of 10,000+ VIP members and have access to our exclusive content.